That's a great question, and it's one that comes up in the myeloma community — especially for those navigating treatment after relapse. While there isn't specific data available here on member experiences with talquetamab after teclistamab for high-risk kappa light chain myeloma, here's what's known about these options:
Show Full Answer
That's a great question, and it's one that comes up in the myeloma community — especially for those navigating treatment after relapse. While there isn't specific data available here on member experiences with talquetamab after teclistamab for high-risk kappa light chain myeloma, here's what's known about these options:
Teclistamab targets BCMA and CD3, bringing T cells into contact with myeloma cells to attack them.
Talquetamab targets a different protein (GPRC5D), which is why it can be a viable next step — it works through a different mechanism, so prior teclistamab use doesn't necessarily rule it out.
CAR T-cell therapy (like cilta-cel/Carvykti) also targets BCMA. Importantly, 1 in 3 people in a major study remained progression-free for 5+ years after a single infusion — a genuinely exciting result. The sequencing of these therapies — talquetamab vs. going straight to CAR-T — really depends on individual factors like:
- Prior treatment history
- Current disease activity and risk profile
- Eligibility for CAR-T (which requires cell harvesting and processing time)
- Overall health and any other considerations your care team flags
A myeloma specialist would be the best person to map out the right sequence for a high-risk case like yours. Asking for a second opinion from a myeloma center of excellence is always a reasonable move too. 💪
May 20
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
